Search results
Results from the WOW.Com Content Network
Blinatumomab linking a T cell to a malignant B cell. Blinatumomab is a bispecific T-cell engager (BiTE). [7] It enables a patient's T cells to recognize malignant B cells. A molecule of blinatumomab combines two binding sites: a CD3 site for T cells and a CD19 site for the target B cells. CD3 is part of the T cell receptor.
Blinatumomab links T cells with CD19 receptors found on the surface of B cells. The Food and Drug Administration (US) and the European Medicines Agency approved this therapy for adults with Philadelphia chromosome-negative relapsed or refractory acute lymphoblastic leukemia.
Revumenib was administered until disease progression, unacceptable toxicity, failure to achieve morphological leukemia-free state by four cycles of treatment, or hematopoietic stem cell transplantation.
A new review reports that nine people taking semaglutide and tirzepatide — the active ingredient in GLP-1 medications — experienced vision issues, including three potentially blinding eye ...
GLP-1 drugs do a lot more than just help you lose weight. They can help your heart, brain, and more, but beware what they might do to muscle and skin. The Terrible—and Amazing—Side Effects of ...
The report also called out different rates of risk factors among different races and ethnic groups. Black women were found to have the highest rate of obesity (57.9%) and Asian women had the ...
Created Date: 8/30/2012 4:52:52 PM
A new study compares the benefits and risks of taking GLP-1 medications for weight loss, including risks of dementia, addiction, heart disease, and gastrointestinal problems, among others.